Abstract
During the past 40 years, somatostatin (SST) has been a subject of intensive research. Apart from its substantial role in the neuroendocrine system, due to its dense localization in various areas in the brain, its functions as a neuromodulator have also been thoroughly investigated. Increasing evidence suggests that SST plays a crucial role in memory and cognition. Synthetic forms, biologically active peptide sequences, SST receptor agonists and SST depleting agents have been applied in animal models and in human studies of a number of neuropsychiatric disorders. The translation of experimental data into clinical use could provide novel therapies in neurodegenerative disorders involving cognitive dysfunctions. However in view of the controversial data reported concerning the different roles of the SST receptor subtypes, and the lack of SST analogs that are able to cross diffusion barriers and act selectively at these receptor subtypes, broader clinical use of SST analogs as cognitive enhancers is limited. This review covers the whole range of available experimental results relating to the behavioral effects of SST, and highlights the potential for further investigations.
Keywords: Alzheimer’s disease, animal models, cognition, Huntington’s disease, learning, memory, Parkinson’s disease, somatostatin
Mini-Reviews in Medicinal Chemistry
Title:Somatostatin and Cognitive Function in Neurodegenerative Disorders
Volume: 13 Issue: 1
Author(s): Gabor Tuboly and Laszlo Vecsei
Affiliation:
Keywords: Alzheimer’s disease, animal models, cognition, Huntington’s disease, learning, memory, Parkinson’s disease, somatostatin
Abstract: During the past 40 years, somatostatin (SST) has been a subject of intensive research. Apart from its substantial role in the neuroendocrine system, due to its dense localization in various areas in the brain, its functions as a neuromodulator have also been thoroughly investigated. Increasing evidence suggests that SST plays a crucial role in memory and cognition. Synthetic forms, biologically active peptide sequences, SST receptor agonists and SST depleting agents have been applied in animal models and in human studies of a number of neuropsychiatric disorders. The translation of experimental data into clinical use could provide novel therapies in neurodegenerative disorders involving cognitive dysfunctions. However in view of the controversial data reported concerning the different roles of the SST receptor subtypes, and the lack of SST analogs that are able to cross diffusion barriers and act selectively at these receptor subtypes, broader clinical use of SST analogs as cognitive enhancers is limited. This review covers the whole range of available experimental results relating to the behavioral effects of SST, and highlights the potential for further investigations.
Export Options
About this article
Cite this article as:
Tuboly Gabor and Vecsei Laszlo, Somatostatin and Cognitive Function in Neurodegenerative Disorders, Mini-Reviews in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1389557511307010034
DOI https://dx.doi.org/10.2174/1389557511307010034 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Role of Wnt Signaling in the Control of Adult Hippocampal Functioning in Health and Disease: Therapeutic Implications
Current Neuropharmacology Metallothionein I+II Expression as an Early Sign of Chronic Relapsing Experimental Autoimmune Encephalomyelitis in Rats
Current Aging Science AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Nutrition and Nutraceuticals in Neuroinflammatory and Brain Metabolic Stress: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Combating Protein Misfolding and Aggregation by Intracellular Antibodies
Current Molecular Medicine Herbal Medicines for the Prevention and Treatment of Alzheimer's Disease
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry <i>Arctium Lappa</i> and Management of Liver Functions to Detoxify the Bloodstream
The Natural Products Journal Chaperonin GroEL: Structure and Reaction Cycle
Current Protein & Peptide Science Editorial: Epigenetics: A Novel Frontier For Drug Discovery
Current Medicinal Chemistry Critical Role of Computer Simulations in Drug Discovery and Development
Current Topics in Medicinal Chemistry Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry